XML 30 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
BUSINESS SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2017
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]
BUSINESS SEGMENT INFORMATION
BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.
Products are sold principally to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. Gross revenues to the three largest pharmaceutical wholesalers in the U.S. as a percentage of global gross revenues were as follows:
 
 
2017
 
2016
 
2015
McKesson Corporation
 
24
%
 
22
%
 
21
%
AmerisourceBergen Corporation
 
18
%
 
18
%
 
16
%
Cardinal Health, Inc.
 
15
%
 
14
%
 
12
%

Selected geographic area information was as follows:
 
 
Revenues
 
Property, Plant and Equipment
Dollars in Millions
 
2017
 
2016
 
2015
 
2017
 
2016
United States
 
$
11,358

 
$
10,720

 
$
8,188

 
$
3,617

 
$
3,865

Europe
 
4,988

 
4,215

 
3,491

 
1,266

 
1,003

Rest of the World(a)
 
3,877

 
3,964

 
4,142

 
118

 
112

Other(b) 
 
553

 
528

 
739

 
—

 
—

Total
 
$
20,776

 
$
19,427

 
$
16,560

 
$
5,001

 
$
4,980

(a)
Includes Japan which represented 7%, 7% and 10% of total revenues in 2017, 2016 and 2015, respectively.
(b)
Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations.
Product revenues and the composition of total revenues were as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2017
 
2016
 
2015
Prioritized Brands
 
 
 
 
 
 
Opdivo
 
$
4,948

 
$
3,774

 
$
942

Eliquis
 
4,872

 
3,343

 
1,860

Orencia
 
2,479

 
2,265

 
1,885

Sprycel
 
2,005

 
1,824

 
1,620

Yervoy
 
1,244

 
1,053

 
1,126

Empliciti
 
231

 
150

 
3

Established Brands
 
 
 
 
 
 
Baraclude
 
1,052

 
1,192

 
1,312

Sustiva Franchise
 
729

 
1,065

 
1,252

Reyataz Franchise
 
698

 
912

 
1,139

Hepatitis C Franchise
 
406

 
1,578

 
1,603

Other Brands
 
2,112

 
2,271

 
3,818

Total Revenues
 
$
20,776

 
$
19,427

 
$
16,560

 
 
 
 
 
 
 
Net product sales
 
$
19,258

 
$
17,702

 
$
14,045

Alliance revenues
 
1,294

 
1,629

 
2,408

Other revenues
 
224

 
96

 
107

Total Revenues
 
$
20,776

 
$
19,427

 
$
16,560